ESBL-producing E. coli and K. pneumoniae: prevalence and antimicrobial susceptibility


Submitted: 17 February 2014
Accepted: 17 February 2014
Published: 30 September 2009
Abstract Views: 823
PDF: 8200
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Infections caused by extended-spectrum beta-lactamase (ESBL) producing E. coli and K. pneumoniae limit therapeutical options.The objective of this study was to evaluate the activity of ciprofloxacin, imipenem, amikacin and piperacillin/tazobactam against ESBL-producing E. coli and K. pneumoniae strains isolated from patients admitted to Ospedali Riuniti, Foggia, over the period January-December 2007. A total of 1013 E. coli and 146 K. pneumoniae were isolated from various clinical specimens. 111/1013 (10.9%) and 24/146 (16.4%) were confirmed as ESBL-producing strains by both the Phoenix system (Becton & Dickinson) and the E-test (bioMérieux, Italia). Both the ESBL producing enterobacteria showed a high degree resistance to ciprofloxacin; in addition, K. pneumoniae exhibited resistance also to piperacillin/tazobactam. Imipenem was the most effective antibiotic with the exception of one strain ESBL-positive K. pneumoniae. A similar pattern was showed by amikacin. In view of the increasing prevalence of ESBL strains it appears important a continuous antimicrobial monitoring.

Miragliotta, G., Di Taranto, A., De Nittis, R., Antonetti, R., Del Prete, R., & Mosca, A. (2009). ESBL-producing E. coli and K. pneumoniae: prevalence and antimicrobial susceptibility. Microbiologia Medica, 24(3). https://doi.org/10.4081/mm.2009.2530

Downloads

Download data is not yet available.

Citations